Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2002

01-02-2002 | Original Article

Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes

Authors: Virginie Dangles, Ilan Halberstam, Antonio Scardino, Jeannine Choppin, Mireille Wertheimer, Sophie Richon, Erwann Quelvennec, Romain Moirand, Jean-Gérard Guillet, Kostas Kosmatopoulos, Dominique Bellet, Dominique Zeliszewski

Published in: Cancer Immunology, Immunotherapy | Issue 12/2002

Login to get access
Metadata
Title
Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes
Authors
Virginie Dangles
Ilan Halberstam
Antonio Scardino
Jeannine Choppin
Mireille Wertheimer
Sophie Richon
Erwann Quelvennec
Romain Moirand
Jean-Gérard Guillet
Kostas Kosmatopoulos
Dominique Bellet
Dominique Zeliszewski
Publication date
01-02-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-001-0248-0

Other articles of this Issue 12/2002

Cancer Immunology, Immunotherapy 12/2002 Go to the issue

Original Article

Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells

Original article

Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells

Original Article

SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients

Original Article

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Original article

Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits